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Patients with schizophrenia have a two- to three-fold increased risk of premature death as compared to patients without this disease. 
It has been established that patients with schizophrenia are at a high risk of developing cardiovascular disease. Moreover, an im-
portant issue that has not yet been explored is a possible existence of a “cerebral” focus that could trigger sudden cardiac death in 
patients with schizophrenia. Along these lines, several structural and functional alterations in the thalamic complex are evident in 
patients with schizophrenia and have been correlated with the symptoms manifested by these patients. With regard to abnormalities 
on the cellular and molecular level, previous studies have shown that schizophrenic patients have fewer neuronal projections from 
the thalamus to the prefrontal cortex as well as a reduced number of neurons, a reduced volume of either the entire thalamus or its 
subnuclei, and abnormal glutamate signaling. According to the glutamate hypothesis of schizophrenia, hypofunctional corticos-
triatal and striatothalamic projections are directly involved in the pathophysiology of the disease. Animal and post-mortem studies 
have provided a large amount of evidence that links the sudden unexpected death in epilepsy (SUDEP) that occurs in patients with 
schizophrenia and epilepsy to thalamic changes. Based on the results of these prior studies, it is clear that further research regarding 
the relationship between the thalamus and sudden cardiac death is of vital importance. 
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SUDDEN CARDIAC DEATH IN SCHIZOPHRENIA: 
GENERAL ASPECTS
Patients with schizophrenia have a two- to three-
fold higher risk of premature death than those without 
schizophrenia. This increased mortality is accounted for 
by a combination of factors, such as lifestyle factors, high 
suicide rates (especially in young male patients soon after 
diagnosis), premature development of cardiovascular 
disease, a high prevalence of metabolic syndrome, 
carbohydrate and lipid metabolic disorders, and, equally 
important but not often mentioned, sudden unexpected 
death.1-3 The exact pathophysiological cause of sudden 
unexpected death in patients with schizophrenia is unknown, 
but it is likely that cardiac arrhythmias play a role.4,5 It has 
been established that people with schizophrenia are at a high 
risk of developing cardiovascular disease and that some 
atypical antipsychotics may be associated with adverse 
cardiovascular events (e.g., QT interval prolongation). 
Together, these risk factors may lead to torsades de pointes 
or sudden cardiac death.4, 6,7 Moreover, an important issue 
that has not yet been explored is the possible existence of a 
“cerebral” focus that could trigger sudden cardiac death in 
patients with schizophrenia. Studies of the pathophysiology 
of sudden unexpected death in epilepsy (SUDEP) have 
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revealed that cardiac bradyarrhythmias that are triggered by 
epileptic activity in the left amygdala, anterior hippocampus, 
orbitofrontal cortex, and insular cortex can occur and lead 
to adverse cardiovascular outcomes.8-10 Through their 
connections with the hypothalamus and pons as well as 
nuclei in the medulla and spinal cord, these regions can 
initiate integrated cardiovascular responses related to 
emotion and motivated behavior that may be inappropriately 
activated during a seizure.10 The thalamus receives 
projections from the insular cortex and amygdala and 
projects to the anterior cingulate cortex, which is the 
executive region involved in exerting emotional control. This 
region, in turn, projects to the hypothalamus, periaqueductal 
grey matter, and the nucleus ambiguus, which control the 
parasympathetic and sympathetic cardiac ganglia and the 
atrioventricular node of the heart10. Heart rate, cardiac 
contractility, and atrioventricular (A-V) conduction may 
therefore be controlled independently by both these brain 
structures and the thalamus.11 Thalamic pathology and 
reduced thalamic volumes have been implicated in the 
pathophysiology of temporal lobe epilepsy, largely due to 
the important connection that the thalamus has with the 
temporal lobe, especially the hippocampus.12 In patients 
with schizophrenia, thalamic pathology has been described 
and may be associated with the occurrence of sudden 
cardiac death. The aim of our paper is to discuss the possible 
association of sudden cardiac death in schizophrenia with 
abnormalities in the thalamic complex.
The presence of anatomical abnormalities in the brains 
of patients with schizophrenia has been well established, 
especially since the introduction of several imaging 
modalities that can be used to perform structural and 
functional brain imaging.13 The structural findings in the 
brains of patients with schizophrenia include dilatation and 
enlargement of the ventricles,14 volume reductions in the 
frontal grey matter,15,16 bilateral reductions in hippocampal 
volume,17 and a reduction in thalamic volumes. These 
findings have all been obtained via structural magnetic 
resonance imaging (MRI) studies.18,19 Because the thalamus 
is heterogeneous, schizophrenia-related changes would 
likely occur in specific thalamic subregions (Figure 1). This 
brain structure is composed of various subnuclei that have 
received special attention in schizophrenia research due to 
to their unique locations and neuronal connectivity.13,20-23 
The thalamus acts as a central relay station that transfers 
peripheral sensory input to the cortex, thereby playing a 
critical role in filtering sensory information, regulating 
cognitive input to the cortex, and mediating corticocortical 
connections between areas that have been especially 
implicated in schizophrenia, such as the frontal and temporal 
cortices.21,24 Recently, Lang and colleagues25 demonstrated 
the presence of a bilateral reduction in thalamic volume 
in a cohort of drug-naive or minimally treated patients 
experiencing initial episodes of psychosis, suggesting that 
such abnormalities are present very early in the course of 
the disease. 
The existence of some structural alterations in the 
brains of schizophrenic patients is supported by data from 
functional studies that have shown the presence of abnormal 
thalamic glucose metabolism in these patients.26,27 In 
patients with schizophrenia, positron emission tomography 
(PET) studies have shown evidence of dysfunction of 
the cortico-cerebellar-thalamic-cortical neuronal circuit. 
This dysfunction contributes to the presence of “cognitive 
dysmetria”, i.e., impaired cognition, as well as other 
symptoms of the disease.28,29 Similarly, reduced levels of 
metabolic activity in the thalamus as measured by PET and 
single-photon emission computed tomography (SPECT) 
studies of cerebral perfusion have been linked to cognitive 
deficits and an increased severity of both positive and 
negative symptoms in schizophrenic patients30. Functional 
MRI studies have shown that these patients have sensory 
processing and attention deficits that involve thalamic 
hypofunction.31-35
THALAMIC ABNORMALITIES ON THE CELLU-
LAR AND MOLECULAR LEVEL
On the cellular level, the density of the parvalbumin-
immunoreactive varicosities in the middle layer of 
the prefrontal cortex has been shown to be lower in 
schizophrenic patients, suggesting that these patients 
have fewer neuronal projections from the thalamus to 
Figure 1 - Photograph of a plastinated brain section from a patient with 
schizophrenia, showing the situation of the thalamus (arrow), which is lo-
cated adjacent to the ventricles. The thalamus is divided into microscopically 
definable subnuclei (e.g., the mediodorsal nucleus) and has connections to 
the prefrontal and temporal cortices. 
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the prefrontal cortex.36 Post-mortem findings of reduced 
thalamic volume, neuronal number, and overall thalamic 
size37 as well as reductions in the size of the mediodorsal 
nucleus, pulvinar nucleus, and ventral posterior thalamic 
nucleus38-42 support the hypothesis that thalamic function 
and the connections between various thalamic nuclei and 
different brain structures in patients with schizophrenia are 
disturbed. In recent 1H-MRSI (proton magnetic resonance 
spectroscopy imaging) studies, reduced N-acetyl-aspartate 
(NAA) levels have been noted to be present in the 
entire thalamus as well as the anterior and mediodorsal 
nuclei of the thalamus in patients with schizophrenia.43-45 
Reductions in NAA levels indicate a loss of the functional 
and structural integrity of neurons. However, a correlation 
between NAA levels and structural parameters has not 
been demonstrated.42-48 Therefore, alterations of NAA 
may be related to the dysfunction of neurons with altered 
glutamatergic neurotransmission.49,50
The glutamate hypothesis of schizophrenia is based on 
the observation that phencyclidine and ketamine, both of 
which block the ion channel of the glutamatergic N-methyl-
D-aspartate (NMDA) receptor, initiate NMDA receptor 
hypofunction and precipitate psychosis,51,52 resulting 
in a final hypoglutamatergic state in the corticostriatal 
projections.53,54 
I n  t h e  s t r i a t o - t h a l amo - co r t i c a l  l oop ,  t h i s 
hypoglutamatergic state may lead to a dysfunction of the 
gamma-amino-butyric acid (GABA)ergic striatothalamic 
projections with consecutive thalamic disinhibition and 
glutamatergic overflow to the cortex.24,55 Accordingly, 
in a 4.0-Tesla MRI spectroscopy study, higher levels of 
glutamine resulting from glutamate breakdown in glial 
cells) have been reported to be found in the thalami of 
unmedicated and chronic schizophrenic patients.56,57 
These results correspond to an increased expression of 
glutamine synthetase and glutaminase. The former converts 
glutamate to glutamine, and the latter converts glutamate 
to glutamine. The upregulation of these enzymes suggests 
an increased rate of glutamate turnover.58 Consistent with 
these findings, the gene expression of the glial glutamate 
transporters [excitatory amino acid transporters 1 and 2 
(EAAT1 and EAAT2)] that remove glutamate from the 
synaptic cleft as well as the expression of a vesicular 
glutamate transporter (VGLUT2) have been shown to be 
increased in patients with schizophrenia.59,60 On the one 
hand, this increased expression may occur as a result of 
transcriptional regulation due to an increased glutamate 
concentration in the synapse. On the other hand, the 
increased expression of these transporters may induce 
a hypoglutamatergic state by decreasing the amount of 
glutamate that is present in the synaptic cleft. The mRNA 
expression of the NMDA receptor subunits NR1, NR2B 
and NR2C, the ionotropic glutamatergic AMPA receptor 
subunits gluR1 and gluR3, the kainate receptor subunit 
KA2, and the polyamine and glycine binding sites of 
the NMDA receptor has been shown to be decreased 
in the mediodorsal and central medial nuclei of the 
thalamus in schizophrenic patients.61,62 These changes 
suggest a diminished glutamatergic activity or abnormal 
glutamatergic innervation of afferent or efferent cortical 
or limbic (hippocampal) structures. In contrast, Clinton 
et al.63 reported the presence of increased protein levels of 
the NR2B subunit and its associated protein PSD95 (which 
targets glutamate receptors to the synaptic membrane, 
modulates receptor activity, and coordinates glutamate 
receptor-related signal transduction) in the thalami of 
patents with schizophrenia. These conflicting results are 
not surprising, since changes in the mRNA levels of a gene 
transcript may not always reflect alterations in protein 
levels.
Altered NAA levels may also be related to the decrease 
in neuropil (dendrites and axons) content that is present 
in patients with schizophrenia. In concordance with 
this hypothesis, in a post-mortem study the levels of the 
synaptic protein rab3a were found to be reduced in the 
left thalamus of schizophrenic patients.64 Alterations in 
the neuropil content of specific brain regions may also 
reflect a reduction in the presence of components of cell 
membranes, i.e., phospholipids. In a 31P-MRSI (phosphorus 
magnetic resonance spectroscopy imaging) study, a 
decrease in the levels of the membrane breakdown product 
glycerophosphoethanolamine has been observed in the 
left thalamus of patients with schizophrenia. This change 
has been viewed as indicative of altered phospholipid 
metabolism in that region.65 Accordingly, in a post-mortem 
study, we showed that there was a decrease in the levels of 
the main membrane phospholipid (phosphatidylcholine) and 
the major myelin membrane components (sphingomyelin 
and galactocerebrosides 1 and 2) in schizophrenic patients. 
In contrast, phosphatidylserine levels were increased in these 
patients, supporting the concept that there is an increased 
breakdown of phospholipids in schizophrenic patients. Since 
these phospholipds are mainly present in the myelin sheath 
of oligodendrocytes, his finding was thought to be indicative 
of oligodendrocyte dysfunction and decreased myelination 
in the thalami of these patients.66
THALAMIC NUCLEAR ABNORMALITIES AND 
SUDDEN CARDIAC DEATH IN SCHIZOPHRENIC 
PATIENTS: AN AVENUE TO BE EXPLORED
In light of the findings mentioned above, the question 
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arises as to whether sudden cardiac death in schizophrenia 
could be related to functional or anatomical changes in the 
thalami of these patients. 
It has long been recognized that, in the healthy brain, 
stimulation of (or the presence of lesions in) certain central 
nervous system structures can lead to morphological and 
functional cardiovascular alterations. Because it has been 
documented that disorders of the central nervous system 
(CNS) can alter cardiovascular function,8 we believe that this 
issue should be deeply explored in schizophrenia research. 
Before these studies are undertaken, it is prudent for us to 
clarify our research background. In a previous study, our 
research group found that the thalamus plays an interesting 
and important role in the cerebral circuits of rats with 
epilepsy67,68. Interestingly, in studies of epilepsy, which is 
the most prevalent serious neurological condition worldwide, 
clinical data suggest that these patients are at a two- to three-
fold higher risk of dying prematurely than those without 
epilepsy. The most common epilepsy-related cause of death 
is SUDEP.69
Following this reasoning, we proposed a new line of 
thinking: because several morphological and/or functional 
changes of the thalamus have been reported to occur in 
patients with epilepsy, it is possible that this brain region 
might also be involved in the occurrence of cardiovascular 
abnormalities and hence SUDEP.
To answer this question, we initially based our 
hypothesis on the elegant study performed by Boyko and 
colleagues.70 The authors showed that bilateral injections 
of kainic acid into the thalamus of adult rats led to 
myocardial necrosis. This effect was particularly marked 
in the lateral posterior thalamic nuclei, suggesting that this 
specific thalamic nucleus has a direct relationship with the 
cardiovascular system. Based on these results, we developed 
an experimental study to reinforce this concept. First, in 
2005, we evaluated the heart rate of rats with epilepsy, both 
in vivo (via electrocardiography) and in an isolated ex vivo 
preparation (via Langendorff preparation).71 Our results from 
the in vivo experiment showed that there were significant 
differences in the mean heart rate of the two groups (control 
animals: 307±9 bpm; animals with epilepsy: 346±7 bpm). 
In contrast, we did not find these differences in the isolated 
ex vivo experiment (control animals: 175±7 bpm; animals 
with epilepsy: 176±6 bpm). These findings suggest that 
some part of the central nervous system (e.g., the thalamic 
nuclei) has the potential to modulate cardiovascular function, 
which could explain the pathophysiology underlying 
SUDEP. In a more recent study, our group (Scorza and 
colleagues, unpublished data) evaluated the heart rate (in 
vivo and isolated ex vivo) of rats with epilepsy before and 
after bilateral lesioning of the lateral posterior nuclei of the 
thalamus. The results showed significant differences in the 
mean heart rate before and after thalamic injury in the in 
vivo experiment. Surprisingly, no differences in heart rate 
could be observed before and after thalamic injury in the 
isolated ex vivo experiment. These observations seem to 
indicate the existence of a specific thalamic modulation of 
cardiac functioning that could support our hypothesis that 
SUDEP occurs due to cardiovascular dysfunction secondary 
to thalamic dysfunction. Finally, based on these results, we 
raised the possibility that the presence of thalamic nuclear 
lesions in people with temporal lobe epilepsy could be 
responsible for some of the processes that culminate in 
SUDEP, and that cardiovascular dysfunction could play a 
significant role in this condition.72
Taking all of these data together, the important question 
arises as to how to use our growing understanding of 
thalamic abnormalities and cardiovascular dysfunction 
in epilepsy patients to guide our examination of the 
possible role that abnormalities in thalamic nuclei play 
in the development of cardiovascular abnormalities in 
schizophrenic patients73. However, from post-mortem 
studies, it is unclear whether thalamic abnormalities or 
antipsychotic treatment contribute to sudden cardiac death, 
since most of the patients in these studies are treated with 
typical and atypical antipsychotics for several decades.
In schizophrenic patients, treatment with antipsychotics 
not only induces QT interval prolongation, but also influences 
thalamic volume and activity. The first study on this topic 
found that both typical and atypical antipsychotic treatment 
increased thalamic volumes in schizophrenic patients.20 
A recent MRI study also found that the use of atypical 
antipsychotics is associated with an enlargement of the 
thalamus.74 However, in another study, the authors found 
that after patients switched from typical neuroleptics to the 
atypical antipsychotic olanzapine, their thalamic volume 
decreased to a normal size as compared to healthy controls.75 
Another study found that patients who were taking atypical 
antipsychotics had decreased thalamic volumes, whereas 
patients treated with typical neuroleptics did not.76 The 
atypical antipsychotic risperidone has been shown to increase 
levels of the neuronal marker NAA in the thalamus.77 
Accordingly, PET studies have shown an increased regional 
cerebral blood flow in the thalamus after treatment with the 
typical neuroleptic haloperidol, whereas olanzapine reduced 
blood flow in this region.78 In animal studies, the typical 
antipsychotic haloperidol as well as the atypical drugs 
clozapine and olanzapine have been shown to induce c-fos 
expression in the thalamus, which is related to activation of 
gene expression in cells in which its expression is induced.79
Hyperactivity of the dopamine D2 neurotransmitter 
system has also been implicated in schizophrenia. This 
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increased dopaminergic signaling may result in disinhibition 
of the thalamus.80 In a PET study, haloperidol was found 
to downregulate the activity of DOPA decarboxylase in 
the thalami of schizophrenic patients, suggesting that 
haloperidol leads to a decrease in the dopamine synthesis 
capacity of the thalamus.81 Additionally, the occurrence 
of akathisia (as a side effect of olanzapine treatment) 
reduced the level of metabolic activity that was present 
in the thalamus of affected patients.82 MRI spectroscopy 
studies have indicated that high glutamine levels in the 
thalamus are reduced after atypical antipsychotic treatment 
is initiated.56,57 Animal models of antipsychotic treatment 
have demonstrated an activation of inhibitory GABAergic 
neurons, a decreased GABAA receptor binding, and an 
altered expression of proteins that interact with glutamate 
transporters.83-85 In summary, the inhibition of thalamic 
activity may be a mode of action of at least atypical 
antipsychotics and may influence patients’ sensitivity to 
cardiac events. 
Where do we go from here? A priority of ours is to raise 
the possibility that the presence of lesions in the thalamic 
nuclei of patients with schizophrenia could represent the 
underlying mechanism of some processes that culminate 
in sudden cardiac death in these patients. We also feel it is 
important to raise the possibility that heart failure may play 
a significant role in this mechanism. Antipsychotic treatment 
may contribute to bradyarrhythmias in schizophrenic 
patients. It is clear that more animal model and clinical 
research needs to be done on this topic. However, in a similar 
manner to what our group has reported about the relationship 
between heart issues and epilepsy, we believe that a 
clear relationship exists between schizophrenia, thalamic 
dysfunction, heart failure, and sudden cardiac death. 
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